Kwality Pharmaceuticals Share News - Latest Updates, Live News & More

Latest news about Kwality Pharmaceuticals

Kwality Pharmaceuticals Reports Strong Q3 FY26 Performance with 46.2% Revenue Growth 8 hrs ago Today

Kwality Pharmaceuticals delivered exceptional Q3 FY26 results with revenue growing 46.2% YoY to INR 123.4 crore and PAT surging 87.8% to INR 16 crore. Nine-month FY26 revenue reached INR 346 crore with 35.9% growth. The company expanded into regulated markets including Mexico and South Africa, completed key regulatory audits, and advanced its bioequivalence programs. With 1000+ formulations across 25+ therapeutic areas and operations in 70+ countries, the company targets INR 650 crore revenue by FY27.

Kwalite Pharmaceuticals Limited Schedules Board Meeting for February 12, 2026 to Consider Q3FY26 Financial Results 10 days ago

Kwality Pharmaceuticals Appoints Bhavesh Mahajan as Additional Independent Director Jan 28, 2026

Kwality Pharmaceuticals Appoints Dr. Bedi as Independent Director Under Regulation 30 Jan 01, 2026

Kwality Pharmaceuticals Reports 32% Revenue Growth in H1 FY26, Maintains Strong Performance Nov 13, 2025

More news about Kwality Pharmaceuticals

06Nov 25

Kwality Pharmaceuticals Bolsters Global Presence with Successful EU-GMP Audit

Kwality Pharmaceuticals Limited has successfully completed a European Union Good Manufacturing Practices (EU-GMP) audit at its Amritsar manufacturing facilities, covering both General and Beta-Lactam units. The audit concluded with no major observations, bringing the company's total EU-approved facilities to four, including General, Beta-Lactam, Cephalosporin, and Oncology units. This achievement enhances Kwality's global market access, quality assurance, and competitive advantage in the pharmaceutical industry.

18Aug 25

Kwality Pharmaceutical Secures Bleomycin Registration in Mexico, Expands Oncology Portfolio

Kwality Pharmaceuticals has obtained product registration for Bleomycin 15 IU per vial in Mexico, expanding its oncology portfolio in regulated markets. The company expects to generate approximately 1.00 million USD in the first year of sales, with supplies commencing before the end of Q2FY26. Bleomycin is used to treat various cancers including Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval strengthens Kwality's global presence and commitment to delivering quality oncology products worldwide.

16Aug 25

Kwality Pharmaceuticals Board Approves Key Reappointments and Sets 42nd AGM Date

Kwality Pharmaceuticals Limited has announced key decisions for its 42nd Annual General Meeting (AGM) on September 9, 2025. The Board approved reappointments of Ramesh Arora as Managing Director, Ajay Kumar Arora, Anju Arora, and Geeta Arora as Whole Time Directors, and Kartik Kapur as Independent Director for five-year terms. Vinod Kumar Sharma's regularization as Additional Independent Director and M/s Rishi Mittal & Associates' appointment as Secretarial Auditors were also approved. The AGM will be held via video conference, with e-voting from September 6-8, 2025, and book closure from September 2-9, 2025. All appointments are subject to shareholder approval at the AGM.

11Aug 25

Kwality Pharmaceuticals Reports Robust 39.8% Revenue Growth in Q1 FY26

Kwality Pharmaceuticals Limited announced robust Q1 FY26 financial results. Consolidated revenue increased by 39.8% to ₹111.80 crore, EBITDA grew by 39% to ₹24.60 crore, and net profit rose by 43% to ₹11.90 crore. The company successfully completed a regulatory audit in Zimbabwe and received multiple new product registrations. Kwality is preparing for EU-GMP and WHO-GMP audits, and has initiated line expansion for its first biological product, Erythropoietin. Management remains confident in achieving the ₹500.00 crore revenue target for FY26.

26Jul 25

Kwality Pharmaceuticals Reshuffles Board, Appoints New Independent Director

Kwality Pharmaceuticals has appointed Dr. Vinod Kumar Sharma as an Additional Non-Executive Independent Director for a five-year term starting July 26, 2025, subject to shareholder approval. Dr. Sharma brings over 30 years of pharmaceutical industry experience. Kiran Kumar Verma has resigned as Independent Director effective July 26, 2025. The company has also restructured its Audit Committee and Nomination and Remuneration Committee following these changes.

19May 25

Kwality Pharmaceuticals Reports Q4 EBITDA Growth and Triple-Digit Profit Surge

Kwality Pharmaceuticals has announced impressive Q4 financial results. Net profit soared 222.22% year-over-year to ₹145.00 crore, while revenue increased by 25% to ₹115.00 crore. EBITDA grew to ₹25.90 crore, though the EBITDA margin slightly decreased to 22.38%. The company's performance indicates strong market positioning and effective operational management.